Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 16/20 | 0.63 |
| ▸ | THRB | P10828 | 16/20 | 0.63 |
| ▸ | EGLN1 | Q9GZT9 | 7/20 | 0.61 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.60 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.60 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.60 |
| ▸ | ASPH | Q12797 | 1/20 | 0.60 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.60 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL523776 | 0.96 | THRA (0.62) | THRATHRBEGLN1BBOX1SLC6A2 | |
| SCHEMBL522357 | 0.93 | THRA (0.62) | THRATHRBEGLN1BBOX1SLC6A2 | |
| SCHEMBL523407 | 0.87 | THRA (0.69) | THRATHRBEGLN1BBOX1SLC6A2 | |
| SCHEMBL4409826 | 0.85 | THRA (0.73) | THRATHRBEGLN1BBOX1SLC6A2 | |
| SCHEMBL523591 | 0.84 | THRA (0.66) | THRATHRBEGLN1BBOX1SLC6A2 | |
| SCHEMBL969046 | 0.84 | THRA (0.86) | THRATHRBEGLN1BBOX1SLC6A2 | |
| SCHEMBL522529 | 0.84 | THRB (0.71) | THRATHRBEGLN1BBOX1SLC6A2 | |
| SCHEMBL522444 | 0.82 | THRA (0.72) | THRATHRBEGLN1BBOX1SLC6A2 | |
| SCHEMBL5338181 | 0.81 | THRA (0.67) | THRATHRBEGLN1BBOX1SLC6A2 | |
| SCHEMBL5338176 | 0.81 | THRA (0.67) | THRATHRBEGLN1BBOX1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1919463-A2 | USE OF HIF 1ALFA MODULATORS FOR TREATMENT OF CANCER | FIBROGEN, INC. (US) | 2008-05-14 | — | — | EP | disclosed |
| WO-2006138511-A2 | USE OF HIF 1ALFA MODULATORS FOR TREATMENT OF CANCER | FIBROGEN, INC. (US) | 2006-12-28 | — | — | WO | disclosed |